Paragon Biosciences is a “global healthcare development and biopharmaceutical investment firm,” that works to “improve lives through biomedical innovation.” Paragon’s companies are handled by leaders in the healthcare industry and “biotech entrepreneurs committed to delivering better outcomes.” Their focus is “improving the lives of patients suffering from the debilitating disease by building innovative biotechnology companies that bring important medicines to the market.”
Chairman, Chief Executive officer, and CEO of Paragon Biosciences, Jeff Aronin, has almost 20 years of experience in “developing global biotech and healthcare innovation companies,” and his “expertise in complex science, rare diseases, and drug development have made him one of the most successful and innovative leaders in the bioscience sector.” Jeff has been the non-executive chairman and president of other affiliated companies and has skills in “strategic and business development, finance, and brand marketing.”
Over the past decade, Paragon Biosciences has had over a dozen FDA approvals, and have had “a success rate on par with much larger companies.” Paragon uses its expertise to “develop and finance innovative biotech companies,” in order to “deeply study patients’ needs, relentlessly to accelerate breakthrough science, and strategically build companies to alleviate suffering and extend life.”
Paragon has a process that includes 3 parts: Identity, Build and Develop. They work to “identify disease where the patient need is highest and treatment availability is most scarce.” They focus on understanding the lives of those they want to help and the science behind the diseases. They “create dynamic companies that redefine what is possible in biotech,” and have a “proven track record for successfully bringing drugs to market.” They are focused on “high unmet medical need” in order to “rapidly advance medicines to help those who lack treatment options.” Many of their medicines are the first or singular approved treatment for certain diseases.
Not only through Paragon, but Jeff Aronin supports countless organizations that are also dedicated to helping patients. “All Paragon companies are committed to making a difference.” It is no wonder their main responsibility remains “Scientific excellence, compassion, and respect for the people [they] strive to help in everything [they] do.”